Perampanel

CAS 380917-97-5 7 current recordsSmall Molecule

Who holds supplier records for Perampanel? 7 organisations hold a current record for Perampanel: an active US FDA Type II Drug Master File. Recorded organisation countries for current records: India (3), Spain (1), China (1) and Netherlands (1); not recorded for 1.

Sources: FDA Drug Master File list, EDQM certification database, FDA Orange Book. Record updated 16 Nov 2026. How we read these records

Cite as: PharmaTek, “Perampanel: DMF and CEP holder records”, record as of 16 Nov 2026, pharmatek.co.uk/directory/api/perampanel

Reading the evidence

  • 7 current records

    Several organisations hold current DMFs or CEPs. Whether any is a usable source for your grade, scale and market still needs qualification.

  • 2 with a company-level GMP certificate on record

    These organisations have at least one current EU or UK GMP certificate somewhere. It is not matched to the site that makes this substance; check the certificate's site and scope.

  • US product patents listed

    The latest patent listed in the FDA Orange Book for an approved product containing Perampanel expires 1 Jul 2026. Product, formulation and method-of-use patents do not by themselves stop the ingredient being supplied or other products being approved.

Current records (7)

Organisations holding an active US FDA Type II Drug Master File or a CEP for Perampanel. Country is the organisation's recorded country, not necessarily the manufacturing site.

India3Spain1China1Netherlands1Country not recorded for 1
Need Perampanel sourced and checked?

The Sourcing Desk contacts candidates, confirms current supply, grade and site, and screens each against its regulatory record, for a buyer-paid fixed fee and never a supplier commission.

Request sourcing help

US product patents and exclusivity

The FDA Orange Book lists patents and exclusivities for specific approved products (33 listed products contain Perampanel). The latest listed patent expires 1 Jul 2026. The latest listed exclusivity ended 14 Jun 2026. These dates are product-specific: they can cover a formulation, a combination or a method of use, and do not on their own show whether the ingredient is protected or whether generics are already approved. Check the individual product entries before planning a launch.

Overview

Perampanel is a non-competitive AMPA receptor antagonist used as an adjunctive therapy for the treatment of partial-onset seizures and generalized tonic-clonic seizures in patients with epilepsy. It works by reducing the excessive excitability of neurons in the brain, which is a hallmark of seizure activity.

Chemical identity

IUPAC name
2-(2-oxo-1-phenyl-5-pyridin-2-yl-3-pyridinyl)benzonitrile
Canonical SMILES
C1=CC=C(C=C1)N2C=C(C=C(C2=O)C3=CC=CC=C3C#N)C4=CC=CC=N4
InChIKey
PRMWGUBFXWROHD-UHFFFAOYSA-N
Synonyms
Fycompa API, e-2007, e2007, er-155055-90, fycompa

Pharmacologic class

As the US FDA states it for this active substance on product listings.

Established pharmacologic class
Noncompetitive AMPA Glutamate Receptor Antagonist
Mechanism of action
AMPA Receptor Antagonists; Cytochrome P450 2C8 Inhibitors; Cytochrome P450 3A4 Inhibitors; UGT1A9 Inhibitors; UGT2B7 Inhibitors

Therapeutic areas

EpilepsySeizure Disorders

Record history

No change to the current records between 13 Nov 2026 and 16 Nov 2026.

Get an email when these records change: at most one a week, only when something changed, and only after you confirm your address. All changes this week

What these records establish

  • An active DMF means a confidential file is held by the FDA and can be referenced; the FDA does not approve or disapprove DMFs.
  • A CEP confirms monograph suitability for the EU market; it is not a GMP certificate, and the holder may not be the manufacturer.
  • Historical records show a past filing, not current supply.
  • Company GMP certificates are matched to the organisation, not to the site making this substance.
  • A substance missing from these registers is not evidence that no supplier exists.

Frequently asked questions

Which organisations hold current supplier records for Perampanel?

7 organisations hold an active US FDA Type II Drug Master File or a CEP for Perampanel: MSN Organics Private Limited (India), CHEMO SMS ENTERPRISE SL (Spain), Intas Pharmaceuticals Ltd. (India), Shandong Loncom Pharmaceutical Co.,ltd. (China), STHREE CHEMICALS PRIVATE LTD, TAPI NL BV (Netherlands) and Zydus Lifesciences Limited (India). A DMF or CEP shows a regulatory filing, not current commercial availability, and the holder is not necessarily the manufacturing site.

Which Perampanel Drug Master Files are active?

MSN Organics Private Limited (DMF 31312, 35608), CHEMO SMS ENTERPRISE SL (DMF 38218), Intas Pharmaceuticals Ltd. (DMF 30649), Shandong Loncom Pharmaceutical Co.,ltd. (DMF 43948), STHREE CHEMICALS PRIVATE LTD (DMF 40753), TAPI NL BV (DMF 30475) and Zydus Lifesciences Limited (DMF 30527). The FDA does not approve or disapprove DMFs; an active DMF can be referenced in an application once its holder issues a letter of authorisation.

Does the FDA Orange Book list patents for products containing Perampanel?

Yes. The latest patent listed for an approved US product containing Perampanel expires 1 Jul 2026, across 33 listed products. These patents protect specific products, formulations or uses. They do not by themselves mean the ingredient is protected, and generic versions of other products may already be approved.

How do I qualify a Perampanel supplier?

Confirm the DMF or CEP is current and covers your grade, obtain the letter of authorisation, identify the actual manufacturing site and check its GMP certificate and FDA inspection history, audit the site or review a recent audit, and run comparable requests for information across more than one candidate.

For suppliers

Do you supply Perampanel?

Send a link to a certificate, registration or filing we have missed or got wrong. We check it against the issuing register before changing anything; information we cannot check against a register is shown as supplier-reported.

Free. Payment never buys an evidence status.